All Healthcare articles
-
White papersHealthcare Pipelines and Paychecks: A Formula for Assessing Executive Pay
Our research suggests that firms with sound executive pay practices yield healthier returns.
-
White papersHealthcare Stocks: An Investing Prescription for Growth and Stability
Healthcare stocks present an exciting investment opportunity, with attractive valuations and strong growth potential driven by demographics and AI adoption. Despite policy uncertainty, healthcare’s defensive nature also offers stability for volatile times.
-
White papersA bitter pill: what tariffs could mean for pharmaceutical firms and the wider healthcare industry
The US government’s proposal to impose tariffs on pharmaceutical imports has ignited a complex debate, intertwining economic, healthcare, and geopolitical considerations. While the initiative aims to bolster domestic manufacturing and reduce reliance on foreign supply chains, it also raises concerns about drug affordability and availability, and has broader implications for the healthcare system.
-
White papersManaging health and care for sustainable performance
The European healthcare sector remains increasingly popular: being more defensive thanks to its long-term demographic drivers, the healthcare sector has always been a meaningful and defensive diversifier in a multi-asset portfolio. Despite a combination of headwinds related to rising interest rates and some operator’s issues, capital value dynamics have diverged across countries and subsectors of health and care.
-
White papersWhat’s Next For Pharmacy Benefit Managers?
These giant middlemen claim they help keep drug costs in check, but scrutiny—and competition—are brewing.
-
White papersTackling inequality and inequity in healthcare
Inequity and inequality are all too common within the modern healthcare system, even in developed countries. The picture is not entirely bleak, however. As impact investors, we have identified several solutions providers finding ways to reduce and overcome the barriers to healthcare.
-
White papersSDG Engagement Equity, Q4 2024 case study
Ansell is domiciled and listed in Australia but is a genuinely global producer of personal protective equipment (PPE) for workers within healthcare and industrial settings.
-
White papersA Positive Prognosis for the Healthcare Property Sector
A segment within the Alternative properties sector, healthcare real estate (life sciences, medical facilities, and seniors housing real estate) is benefitting greatly from the growing demand for healthcare research and services fueled by the aging of the massive Baby Boomer age cohort.
-
White papersThe power of additionality: Why impact investing should focus on building companies that otherwise wouldn’t exist
As impact investing continues to grow, one of its most essential principles—additionality—is becoming a central topic of conversation. In simple terms, additionality refers to the idea that an investment has a positive societal impact that would not have occurred without the intervention of that capital. While it’s easy to focus on financial returns and measurable impact metrics like carbon reduction or jobs created, additionality raises a more profound question: Are these companies addressing problems that would remain unsolved without their innovation?
-
White papersFive growth themes for the next five years
Recent months have seen early signs of a market rotation, from a narrow set of growth leaders to a broader array of companies. While investors are not bailing on Big Tech, many are concerned about concentration risk and excessive exposure to these companies in market-cap-weighted indices.
-
White papersObesity drugs: a lifeline for global healthcare systems
The global population is expanding and at the same time, life expectancy is increasing. Chronic diseases are on the rise and the threat of infectious diseases is constantly evolving. All of this is set to place a massive strain on already-stretched healthcare systems.
-
White papersThe Generational Divide
Leveraging data from the Retirement Survey & Insights Report 2023, this supplemental report examines the challenges faced by each working generation (working Baby Boomers, Generation X, Millennials, and Generation Z) in an effort to better understand their retirement journey.
-
White papersToday’s healthcare treatment, tomorrow’s healthcare innovation
While treatments for obesity have dominated the healthcare investment narrative over the past 18 months, they are by no means the only secular growth story. We see the life sciences industry as well positioned to benefit from structural trends.
-
White papersThe Equity Breakdown: Parsing the Key Debate in Five Sectors
Five of our senior equity analysts weigh in on the crucial conversation in each of their sectors.
-
White papersHealthcare Stocks: Testing the Vital Signs of Managed Care Providers
Questions are being asked about the US managed care industry, but some businesses are equipped to rise to the challenge.
-
White papersThe health care breakthrough that’s not an obesity drug
You’ve heard of computer hacking, now meet gene hacking. In an age of remarkable health care innovation, scientists are manipulating human DNA to find new ways to treat diseases.
-
White papersAre Healthcare Stocks a Risky Prescription in a US Election Year?
Despite conventional wisdom, political uncertainty doesn’t necessarily pose acute risks to the healthcare sector.
-
White papersETF investing – How AI and 3D printing are shaping the future of healthcare
Genomic engineering is the manipulation of an organism’s genes by introducing, eliminating or rearranging specific genes using the methods of modern molecular biology. The technology will enable the analysis of patients’ DNA, and the diagnosis and treatment of diseases. And what’s good for patients can also be interesting for investors.
-
White papersHealthcare investing - 2024 outlook brighter on compelling valuations and easing headwinds
2023 was a tough year for healthcare investing, resulting in the sector lagging the broader indices by the widest margin since 1999. We believe the outlook for 2024 is much more favourable as the sector’s valuation is highly compelling, while many of the headwinds are abating.
-
White papersListening for the Quiet: Discovering the Real Data Advantage
Taking time to sort through all the noise around artificial intelligence (AI) can uncover the quiet: promising companies with strong potential to benefit from their access to quality data.
